A combination treatment approach using two chemotherapy drugs improved treatment response and progression-free survival in patients with advanced pancreatic neuroendocrine tumors, according to a recent clinical trial published ...
Apr 13, 2023
0
4
Among patients with previously treated HER2-positive metastatic breast cancer, those who received pyrotinib plus capecitabine had longer overall survival than those who received lapatinib (Tykerb) plus capecitabine, according ...
Dec 8, 2021
0
2
A cancer cell is like a racecar, speeding through the process of cellular replication. But it has to stop at the G2M cell cycle checkpoint, where a race inspector called Wee1 checks it over for damage—cells with intact ...
Apr 1, 2019
0
1
Treating patients who had early-stage triple-negative breast cancer with the chemotherapy agent capecitabine after they completed surgery and standard chemotherapy did not significantly improve disease-free or overall survival ...
Dec 5, 2018
0
0
A study by researchers at the University of North Carolina Eshelman School of Pharmacy and Lineberger Comprehensive Cancer Center determined the cost savings for a generic version of an orally administered cancer treatment ...
Sep 11, 2017
0
0
(HealthDay)—Capecitabine (Xeloda) can extend the lives of patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have residual invasive disease after receipt of neoadjuvant chemotherapy, ...
Jun 1, 2017
0
1
Patients who take capecitabine after surgery for bile duct cancer live for almost a year and a half longer than those not given the drug, according to the results of a Cancer Research UK funded trial presented at the 2017 ...
May 18, 2017
0
152
(HealthDay)—Guidelines relating to the appropriate adjuvant regimen for patients with pancreatic cancer have been updated in light of new evidence, according to a special article published online April 11 in the Journal ...
Apr 17, 2017
0
2
Something as seemingly harmless as a heartburn pill could lead cancer patients to take a turn for the worse. A University of Alberta study published in journal JAMA Oncology discovered that proton pump inhibitors (PPIs), ...
Dec 16, 2016
0
2
Locally advanced rectal cancer patients who receive preoperative radiation therapy with either irinotecan plus capecitabine or oxaliplatin plus capecitabine have a four-year overall survival rate of 85 percent and 75 percent, ...
Jan 9, 2015
0
10
Capecitabine (INN) ( /keɪpˈsaɪtəbiːn/) (Xeloda, Roche) is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.[citation needed] The activation of capecitabine follows a pathway with three enzymatic steps and two intermediary metabolites, 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouridine (5'-DFUR), to form 5-fluorouracil.[citation needed]
This text uses material from Wikipedia, licensed under CC BY-SA
